Antimicrobial Agents Practice Questions

Q: Which of the following drugs can cause ototoxicity?

Amikacin. ***Amikacin*** - **Amikacin** is an **aminoglycoside antibiotic** and is **the most well-known** drug among the options for causing **ototoxicity** (damage to the ear, leading to hearing loss, tinnitus, or vestibular dysfunction) [1], [2]. - This adverse effect is **dose-dependent** and related to the **cumulative dose** and **peak plasma levels** of the drug [2]. - Aminoglycosides cause both **cochlear toxicity** (hearing loss) and **vestibular toxicity** (balance problems) [1], [2]. *Metronidazole* - **Metronidazole** is an antibiotic and antiprotozoal drug that primarily causes **gastrointestinal upset** and a **metallic taste** in the mouth. - While it can cause neurological side effects like **peripheral neuropathy**, **ototoxicity is not a typical adverse effect** associated with metronidazole. *Amoxicillin* - **Amoxicillin** is a common **penicillin-class antibiotic** generally considered safe with a good side effect profile. - Its most common side effects are **gastrointestinal disturbances** like nausea, vomiting, and diarrhea, as well as **allergic reactions** and skin rashes. - **Ototoxicity is not a recognized side effect** of beta-lactam antibiotics. *Ciprofloxacin* - **Ciprofloxacin** is a **fluoroquinolone antibiotic** primarily associated with side effects like **tendinopathy**, **arthropathy**, and **QT prolongation**. - While fluoroquinolones **can cause ototoxicity** (tinnitus, hearing disturbances), this is **much less common and less severe** compared to aminoglycosides. - Ciprofloxacin is not the primary drug associated with ototoxicity in this context.

Q: Which drug is used as first-line treatment for acute bacterial sinusitis?

Amoxicillin-clavulanate. ***Amoxicillin-clavulanate*** - This is generally recommended as the **first-line antibiotic** for acute bacterial sinusitis in adults and children due to its broad spectrum of activity against common respiratory pathogens like *Streptococcus pneumoniae* and *Haemophilus influenzae*, including beta-lactamase-producing strains. - The **clavulanate component** helps overcome bacterial resistance to amoxicillin by inhibiting beta-lactamase enzymes, making it effective against a wider range of bacteria. *Ciprofloxacin* - This is a **fluoroquinolone** antibiotic, typically reserved for **second-line treatment** of acute bacterial sinusitis, especially in cases of antibiotic failure or severe penicillin allergy. - Its use is generally avoided as a first-line choice due to concerns about increasing **antibiotic resistance** and potential side effects like tendinopathy and *Clostridioides difficile* infection. *Azithromycin* - This is a **macrolide antibiotic** that may be used in patients with **penicillin allergy**, but it's not considered first-line for acute bacterial sinusitis because of increasing rates of **macrolide resistance** among *Streptococcus pneumoniae*. - Its **narrower spectrum** against common sinusitis pathogens compared to amoxicillin-clavulanate makes it less ideal as initial therapy. *Doxycycline* - This is a **tetracycline antibiotic** that can be considered as an alternative for patients with **penicillin allergy** for acute bacterial sinusitis. - However, it is not typically preferred as a first-line agent over amoxicillin-clavulanate, given its potential side effects and the established efficacy and safety profile of beta-lactams.

Q: Which antiviral drug class is most effective in treating influenza by inhibiting the neuraminidase enzyme?

Neuraminidase inhibitors. ***Neuraminidase inhibitors*** - This class of drugs, which includes **oseltamivir** and **zanamivir**, specifically targets the **neuraminidase** enzyme of the influenza virus. - By inhibiting neuraminidase, these drugs prevent the release of newly formed **virions** from infected cells, thus stopping viral propagation and spread. *Protease inhibitors* - These drugs are primarily used in the treatment of **HIV** and **hepatitis C virus** infections. - They work by blocking the activity of viral **protease enzymes** essential for cleaving viral polyproteins into functional proteins. *Nucleotide analogs* - This class of antiviral drugs, such as **acyclovir** and **remdesivir**, is used to treat various viral infections like **herpesviruses** and **Ebola**. - They act by mimicking natural **nucleotides** and are incorporated into growing viral DNA or RNA chains, leading to **chain termination** and inhibition of viral replication. *Integrase inhibitors* - These drugs are specifically used in the treatment of **HIV infection**. - They work by blocking the activity of the **HIV integrase enzyme**, which is responsible for integrating viral DNA into the host cell's genome.

Q: In the context of HIV treatment, what is the primary purpose of combining multiple antiretroviral medications?

To prevent the development of resistance. ***To prevent the development of resistance*** - HIV has a **high mutation rate** due to its RNA genome and error-prone reverse transcriptase, allowing it to rapidly develop resistance to single antiretroviral drugs. - Combining multiple drugs that target different stages of the viral life cycle ensures that even if one drug's target mutates, other drugs can still inhibit viral replication, thereby **suppressing viral evolution** and minimizing resistance. *To reduce the pill burden* - While single-pill regimens combining multiple drugs exist, the primary goal of combining different antiretrovirals is not to reduce the number of pills, but rather to **enhance efficacy and prevent resistance**. - Reducing pill burden is a secondary benefit or an aim of drug formulation, not the fundamental purpose of combination therapy itself. *To increase the mutation rate of the virus* - This statement is incorrect; the goal of HIV treatment is to **decrease viral replication** and thus reduce the opportunity for new mutations to occur, not to increase them. - An increased mutation rate would be detrimental, leading to more rapid drug resistance and treatment failure. *To target different organs infected with HIV* - While HIV can infect various cell types and organs, the primary goal of combination antiretroviral therapy (cART) is to **reduce the viral load throughout the body** by inhibiting viral replication, regardless of the specific organ. - Different drugs target different steps of the viral life cycle, not necessarily different organ systems, but achieving systemic viral suppression benefits all affected tissues.

Q: A patient undergoing chemotherapy requires prophylactic treatment to prevent infection. Which drug is commonly prescribed for Pneumocystis pneumonia prophylaxis?

Trimethoprim-sulfamethoxazole. ***Trimethoprim-sulfamethoxazole*** - This combination antibiotic is the **most commonly prescribed and highly effective** agent for preventing **Pneumocystis pneumonia (PCP)** in immunocompromised patients, including those undergoing chemotherapy. - It works by inhibiting **folate synthesis** in *Pneumocystis jirovecii*, thereby preventing its proliferation. *Doxycycline* - **Doxycycline** is a tetracycline antibiotic primarily used for bacterial infections like pneumonia and skin infections, or for malaria prophylaxis. - It is **not effective** against *Pneumocystis jirovecii* and therefore not used for PCP prophylaxis. *Sulfadiazine* - **Sulfadiazine** is a sulfonamide antibiotic that can be used to treat toxoplasmosis, but it is **not the first-line or most effective agent** for PCP prophylaxis when used alone. - It is a component of trimethoprim-sulfamethoxazole, where the combined action is crucial for PCP prevention. *Clindamycin* - **Clindamycin** is a lincosamide antibiotic primarily used for anaerobic bacterial infections and certain protozoal infections like toxoplasmosis in combination with pyrimethamine. - It has **no significant role** in the prevention of **Pneumocystis pneumonia**.

Q: Which antiviral drug inhibits DNA polymerase, effectively preventing viral replication in herpes viruses?

Acyclovir. ***Acyclovir*** - Acyclovir is a **guanosine analog** that is selectively phosphorylated by **herpes viral thymidine kinase** within infected cells. - The activated form then inhibits **viral DNA polymerase**, leading to chain termination and preventing viral replication. *Oseltamivir* - Oseltamivir is an **antiviral medication** used to treat and prevent **influenza A and B** by inhibiting the viral enzyme **neuraminidase**. - It does not target **herpes viruses** or their **DNA polymerase**. *Ritonavir* - Ritonavir is an **antiretroviral drug** primarily used to treat **HIV infection**, often as a **pharmacokinetic booster** for other protease inhibitors. - It works by inhibiting **HIV protease**, not DNA polymerase of herpes viruses. *Zidovudine* - Zidovudine (AZT) is a **nucleoside reverse transcriptase inhibitor (NRTI)** used in the treatment of **HIV infection**. - It works by inhibiting **reverse transcriptase**, an enzyme unique to retroviruses, and is not active against herpes viral DNA polymerase.

Q: A 60-year-old man is diagnosed with hospital-acquired bacterial endocarditis and empiric broad-spectrum coverage is needed. Which beta-lactamase inhibitor combined with an anti-pseudomonal penicillin provides the broadest coverage in this context?

Tazobactam. ***Tazobactam*** - **Tazobactam** combined with **piperacillin** (piperacillin-tazobactam) provides the **broadest spectrum coverage** among beta-lactamase inhibitor combinations, particularly for hospital-acquired infections. - It is effective against a wide range of bacteria including **ESBL-producing organisms**, Pseudomonas aeruginosa, and many Gram-positive and Gram-negative bacteria. - In the context of **hospital-acquired endocarditis** where broad empiric coverage is needed, piperacillin-tazobactam is frequently chosen due to its **enhanced activity against resistant organisms** and coverage of nosocomial pathogens. *Sulbactam* - **Sulbactam** is combined with ampicillin and is effective against **beta-lactamase-producing Staphylococcus aureus** and certain Gram-negative bacteria. - While useful in some endocarditis cases (particularly community-acquired), it has a **narrower spectrum** compared to tazobactam and lacks reliable anti-pseudomonal activity. *Clavulanic acid* - **Clavulanic acid** is combined with amoxicillin or ticarcillin and covers **Gram-positive and some Gram-negative bacteria**. - Its spectrum of beta-lactamase inhibition is **more limited** than tazobactam, particularly against ESBL-producing organisms common in hospital settings. - Amoxicillin-clavulanate is rarely used for endocarditis treatment. *All of the options* - While all three are beta-lactamase inhibitors used in various infections, **tazobactam** (in combination with piperacillin) provides the **broadest spectrum** and is most appropriate for empiric therapy in hospital-acquired endocarditis requiring coverage of resistant organisms. - The choice depends on **suspected pathogen**, local resistance patterns, and infection severity, but for broad empiric coverage in nosocomial infections, piperacillin-tazobactam is preferred.

Q: Which drug was among the first antivirals to receive emergency authorization for COVID-19 treatment and works by inhibiting viral RNA polymerase?

Remdesivir. ***Remdesivir*** - **Remdesivir** is an **adenosine nucleotide analog** that inhibits viral **RNA-dependent RNA polymerase (RdRp)**, thereby disrupting **viral replication**. - It was **one of the first antiviral drugs** to receive emergency use authorization for treating COVID-19, particularly in **hospitalized patients with severe disease**. - Administered **intravenously**, it directly targets the viral replication machinery. *Paxlovid (nirmatrelvir-ritonavir)* - While highly effective in reducing viral replication, **Paxlovid** is a **protease inhibitor combination** with a different mechanism of action. - **Nirmatrelvir** targets the **SARS-CoV-2 main protease (Mpro)**, not RNA polymerase, preventing the virus from processing polyproteins necessary for replication. - It received authorization **later** than remdesivir and is given **orally** for outpatient use. *Molnupiravir* - **Molnupiravir** is an oral antiviral that induces **lethal mutations in viral RNA** (error catastrophe), a mechanism distinct from **RNA polymerase inhibition**. - While it reduces viral replication, it does not work by inhibiting viral RNA polymerase specifically. *Ibuprofen* - **Ibuprofen** is a **non-steroidal anti-inflammatory drug (NSAID)** used to manage **fever, pain, and inflammation** associated with COVID-19. - It has **no direct antiviral activity** and does not inhibit viral replication—it provides purely **symptomatic relief**.

Q: A patient with tuberculosis is given a first-line treatment regimen that includes a drug that inhibits mycolic acid synthesis. Which drug is appropriate?

Isoniazid. ***Isoniazid*** - **Isoniazid** is a prodrug that, once activated by the bacterial catalase-peroxidase enzyme **KatG**, inhibits **mycolic acid synthesis**. - Its mechanism involves interfering with the synthesis of **mycolic acids**, which are essential components of the **mycobacterial cell wall**, leading to its bactericidal effect. *Rifampin* - **Rifampin** inhibits **bacterial DNA-dependent RNA polymerase (DDRP)**, thereby blocking RNA synthesis. - This drug is known for its ability to penetrate macrophages and act on bacteria within these cells, and it contributes to the sterilizing activity of TB regimens. *Pyrazinamide* - **Pyrazinamide** is a prodrug converted to pyrazinoic acid in acidic environments, which disrupts **mycobacterial metabolism** and membrane function. - Its exact mechanism is not fully understood, but it is known to be effective against **intracellular M. tuberculosis** in acidic phagosomal environments. *Ethambutol* - **Ethambutol** inhibits **arabinosyl transferase**, an enzyme involved in the synthesis of the **arabinogalactan component of the mycobacterial cell wall**. - This inhibition prevents the formation of the complex mycobacterial cell wall, making the bacteria more susceptible to other anti-TB drugs.

Question 1

Which of the following drugs can cause ototoxicity?

Accepted Answer

Amikacin

Answer

Metronidazole

Answer

Amoxicillin

Answer

Ciprofloxacin

Question 2

Which drug is used as first-line treatment for acute bacterial sinusitis?

Accepted Answer

Amoxicillin-clavulanate

Answer

Ciprofloxacin

Answer

Azithromycin

Answer

Doxycycline

Question 3

Which antiviral drug class is most effective in treating influenza by inhibiting the neuraminidase enzyme?

Accepted Answer

Neuraminidase inhibitors

Answer

Protease inhibitors

Answer

Nucleotide analogs

Answer

Integrase inhibitors

Question 4

A patient with a history of recurrent cold sores is being evaluated for antiviral therapy. Which phase of the herpes simplex virus lifecycle is targeted by acyclovir, and why is it effective?

Accepted Answer

Viral DNA replication; acyclovir inhibits viral DNA polymerase

Answer

Viral entry; acyclovir blocks viral fusion with the host cell membrane

Answer

Latency; acyclovir induces viral genome degradation

Answer

Viral assembly; acyclovir prevents virion packaging

Question 5

In the context of HIV treatment, what is the primary purpose of combining multiple antiretroviral medications?

Accepted Answer

To prevent the development of resistance

Answer

To reduce the pill burden

Answer

To increase the mutation rate of the virus

Answer

To target different organs infected with HIV

Question 6

A patient undergoing chemotherapy requires prophylactic treatment to prevent infection. Which drug is commonly prescribed for Pneumocystis pneumonia prophylaxis?

Accepted Answer

Trimethoprim-sulfamethoxazole

Answer

Doxycycline

Answer

Sulfadiazine

Answer

Clindamycin

Question 7

Which antiviral drug inhibits DNA polymerase, effectively preventing viral replication in herpes viruses?

Accepted Answer

Acyclovir

Answer

Oseltamivir

Answer

Ritonavir

Answer

Zidovudine

Question 8

A 60-year-old man is diagnosed with hospital-acquired bacterial endocarditis and empiric broad-spectrum coverage is needed. Which beta-lactamase inhibitor combined with an anti-pseudomonal penicillin provides the broadest coverage in this context?

Accepted Answer

Tazobactam

Answer

Sulbactam

Answer

Clavulanic acid

Answer

All of the options

Question 9

Which drug was among the first antivirals to receive emergency authorization for COVID-19 treatment and works by inhibiting viral RNA polymerase?

Accepted Answer

Remdesivir

Answer

Paxlovid (nirmatrelvir-ritonavir)

Answer

Ibuprofen

Answer

Molnupiravir

Question 10

A patient with tuberculosis is given a first-line treatment regimen that includes a drug that inhibits mycolic acid synthesis. Which drug is appropriate?

Accepted Answer

Isoniazid

Answer

Rifampin

Answer

Pyrazinamide

Answer

Ethambutol

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?